GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » Cyclically Adjusted PB Ratio

KNBIF (Kane Biotech) Cyclically Adjusted PB Ratio : (As of May. 31, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Kane Biotech Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kane Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kane Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech Cyclically Adjusted PB Ratio Chart

Kane Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 4.03 4.42 27.87 -

Kane Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.87 - - - -

Competitive Comparison of Kane Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Kane Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Cyclically Adjusted PB Ratio falls into.


;
;

Kane Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kane Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Kane Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.008/127.3637*127.3637
=-0.008

Current CPI (Dec. 2024) = 127.3637.

Kane Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201503 0.031 99.789 0.040
201506 0.021 100.500 0.027
201509 0.016 100.421 0.020
201512 0.013 99.947 0.017
201603 0.008 101.054 0.010
201606 0.044 102.002 0.055
201609 0.033 101.765 0.041
201612 0.022 101.449 0.028
201703 0.019 102.634 0.024
201706 0.007 103.029 0.009
201709 0.037 103.345 0.046
201712 0.021 103.345 0.026
201803 0.018 105.004 0.022
201806 0.011 105.557 0.013
201809 0.003 105.636 0.004
201812 -0.009 105.399 -0.011
201903 -0.015 106.979 -0.018
201906 0.000 107.690 0.000
201909 -0.004 107.611 -0.005
201912 0.006 107.769 0.007
202003 0.004 107.927 0.005
202006 0.001 108.401 0.001
202009 -0.005 108.164 -0.006
202012 -0.011 108.559 -0.013
202103 -0.016 110.298 -0.018
202106 -0.015 111.720 -0.017
202109 -0.019 112.905 -0.021
202112 -0.026 113.774 -0.029
202203 -0.034 117.646 -0.037
202206 -0.030 120.806 -0.032
202209 -0.034 120.648 -0.036
202212 -0.038 120.964 -0.040
202303 -0.045 122.702 -0.047
202306 -0.052 124.203 -0.053
202309 -0.052 125.230 -0.053
202312 -0.060 125.072 -0.061
202403 -0.066 126.258 -0.067
202406 -0.004 127.522 -0.004
202409 -0.004 127.285 -0.004
202412 -0.008 127.364 -0.008

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kane Biotech  (OTCPK:KNBIF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kane Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.